Actinium Pharmaceuticals, Inc. — Director's Dealing 2017

Mar 16, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Actinium Pharmaceuticals, Inc. (ATNM)
CIK: 0001388320
Period of Report: 2017-03-14

Reporting Person: SETH SANDESH (Director, Executive Chairman)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-03-14	Warrant to purchase common stock	$0.78	J	64746	Acquired	2022-02-11	Common Stock (64.746)	Direct
2017-03-14	Warrant to purchase common stock	$0.78	J	99619	Acquired	2022-02-11	Common Stock (99619)	Indirect
2017-03-14	Warrant to purchase common stock	$2.34	J	57212	Disposed	2018-01-28	Common Stock (57212)	Direct
2017-03-14	Warrant to purchase common stock	$2.34	A	57212	Acquired	2022-02-11	Common Stock (57.212)	Direct
2017-03-14	Options to purchase common stock	$1.39	A	750000	Acquired	2027-03-14	Common Stock (750000)	Direct

Footnotes

F1: Certain warrants were issued to Mr. Seth as part of investment banking and advisory services either prior to and outside of Mr. Seth's role as a Board Member and subsequently Executive Chairman and are not compensation for Board or Executive Chairman services to the Company. The Executive Chairman has refrained from exercising certain warrants that are or have been in the money for most of their term in order to align with the long term interests of the Company. In order to maintain that alignment on March 14. 2017, the warrant was amended to extend the term until February 11, 2022. The warrant issued for 99,619 shares was issued to Amrosan LLC, an entity affiliated with Mr. Seth's family.

F2: Certain warrants were issued to Mr. Seth as part of investment banking and advisory services either prior to and outside of Mr. Seth's role as a Board Member and subsequently Executive Chairman and are not compensation for these latter services to the Company. The Executive Chairman has refrained from exercising certain warrants that are or have been in the money for most of their term in order to align with the long term interests of the Company. In order to maintain that alignment on March 14, 2017 the Company cancelled a Warrant in the amount of 57,212, shares and issued a new warrant with a term until February 11, 2022.

F3: Pursuant to the terms of the company's Amended and Restated 2013 Stock Plan, 2% of the options shall vest each month from the date of grant. In addition, 100,000 options are subject to cancellation based on the obtainment of certain milestones.